Pientzehuang begins phase IIa trial for PZH2108, announces leadership changes

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. announced the successful enrollment of the first subject in the Phase IIa clinical trial for its innovative Class 1 drug, PZH2108 tablets. This marks a significant step in developing a new treatment for cancer pain, following Phase I trials that showed good safety and tolerability. The company has invested approximately CNY 61 million in the drug's research and development to date.

Concurrently, the company is undergoing significant governance reforms. The board of directors approved the removal of the supervisory board and supervisors, with their functions transferred to the board's audit committee. The company will also establish an employee representative director position. These changes necessitate revisions to company rules, which await approval at an upcoming extraordinary general meeting.

Furthermore, the board accepted the resignation of Shi Yixiong as board secretary due to work adjustments. Mr. Shi will continue as deputy general manager. The board approved the appointment of He Wei as the new board secretary. Lin Huijuan was also nominated as a non-independent director candidate.